NFA
LRMR icon

Nationwide Fund Advisors’s Larimar Therapeutics LRMR Stock Holding History

Nationwide Fund Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-887
Closed -$37K – 1176
2017
Q3 		$37K Hold
887
– – ﹤0.01% 3066
2017
Q2 		$37K Sell
887
-778
-47% -$39.8K ﹤0.01% 3078
2017
Q1 		$93K Buy
1,665
+421
+34% +$20.9K ﹤0.01% 2864
2016
Q4 		$47K Sell
1,244
-8
-0.6% -$324 ﹤0.01% 3012
2016
Q3 		$50K Sell
1,252
-25
-2% -$1.14K ﹤0.01% 3045
2016
Q2 		$92K Buy
1,277
+157
+14% +$12.4K ﹤0.01% 2945
2016
Q1 		$90K Hold
1,120
– – ﹤0.01% 2865
2015
Q4 		$85K Sell
1,120
-1,328
-54% -$213K ﹤0.01% 2895
2015
Q3 		$938K Hold
2,448
– – ﹤0.01% 1761
2015
Q2 		$1.02M Buy
2,448
+1,288
+111% +$539K ﹤0.01% 1838
2015
Q1 		$551K Sell
1,160
-264
-19% -$125K ﹤0.01% 2187
2014
Q4 		$527K Buy
1,424
+658
+86% +$170K ﹤0.01% 2154
2014
Q3 		$181K Buy
+766
New +$174K ﹤0.01% 2744

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nationwide Fund Advisors's LRMR Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2017, closing a stake of 887 shares — an estimated $37K sold.

Nationwide Fund Advisors first reported a position in LRMR in Q3 2014 and held it in 13 quarters. The position peaked at $1.02M in Q2 2015. 56 funds tracked by Wall St. Rank hold LRMR as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Larimar Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 887 Larimar Therapeutics shares in Q4 2017, an estimated $37K.
  • Nationwide Fund Advisors first reported a position in Larimar Therapeutics in Q3 2014 and held it in 13 quarters.
  • Nationwide Fund Advisors's Larimar Therapeutics position peaked at $1.02M in Q2 2015.
  • 56 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.